These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9338548

  • 1. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.
    Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A.
    J Allergy Clin Immunol; 1997 Oct; 100(4):527-35. PubMed ID: 9338548
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
    Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
    [Abstract] [Full Text] [Related]

  • 3. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
    Ekholm D, Mulloy JC, Gao G, Degerman E, Franchini G, Manganiello VC.
    Biochem Pharmacol; 1999 Sep 15; 58(6):935-50. PubMed ID: 10509746
    [Abstract] [Full Text] [Related]

  • 4. Evidence to suggest that the phosphodiesterase 4 isoenzyme is present and involved in the proliferation of umbilical cord blood mononuclear cells.
    Banner KH, Dimitriou G, Kinali M, Page CP, Greenough A.
    Clin Exp Allergy; 2000 May 15; 30(5):706-12. PubMed ID: 10792363
    [Abstract] [Full Text] [Related]

  • 5. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
    Banner KH, Roberts NM, Page CP.
    Br J Pharmacol; 1995 Dec 15; 116(8):3169-74. PubMed ID: 8719792
    [Abstract] [Full Text] [Related]

  • 6. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM, Barnes PJ, Meja K, Giembycz MA.
    Mol Pharmacol; 1995 Oct 15; 48(4):747-57. PubMed ID: 7476903
    [Abstract] [Full Text] [Related]

  • 7. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1997 May 15; 121(2):221-31. PubMed ID: 9154331
    [Abstract] [Full Text] [Related]

  • 8. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
    Essayan DM, Huang SK, Kagey-Sobotka A, Lichtenstein LM.
    J Allergy Clin Immunol; 1997 Jan 15; 99(1 Pt 1):28-37. PubMed ID: 9003208
    [Abstract] [Full Text] [Related]

  • 9. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages.
    Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanović R, Schudt C, Wendel A, Church MK, Shute JK.
    Clin Exp Allergy; 1995 Jul 15; 25(7):625-33. PubMed ID: 8521181
    [Abstract] [Full Text] [Related]

  • 10. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes.
    Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanović R, Church MK, Shute JK.
    Clin Exp Allergy; 1995 Jul 15; 25(7):616-24. PubMed ID: 8521180
    [Abstract] [Full Text] [Related]

  • 11. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
    Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS.
    Br J Pharmacol; 1999 Dec 15; 128(7):1393-8. PubMed ID: 10602317
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA.
    Br J Pharmacol; 1996 Jun 15; 118(3):649-58. PubMed ID: 8762090
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.
    Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K, Kaminuma O.
    Clin Exp Immunol; 2002 Jun 15; 128(3):460-6. PubMed ID: 12067300
    [Abstract] [Full Text] [Related]

  • 19. Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells.
    Banner KH, Hoult JR, Taylor MN, Landells LJ, Page CP.
    Biochem Pharmacol; 1999 Nov 01; 58(9):1487-95. PubMed ID: 10513992
    [Abstract] [Full Text] [Related]

  • 20. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
    Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin SL.
    Mol Pharmacol; 1995 Jun 01; 47(6):1164-71. PubMed ID: 7603456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.